Five Under 5: Top Oncology Videos for the Week of 6/1/2026

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

The Efficacy of Daraxonrasib in Previously Treated mPDAC From RASolute 302: Daniel King, MD, PhD

Daniel King, MD, PhD, director of Research and Development at the Center for Genomic Medicine at Northwell Health Cancer Institute, discussed key efficacy data from the phase 3 RASolute 302 trial (NCT06625320) investigating daraxonrasib (RMC-6236) in patients with previously treated metastatic pancreatic adenocarcinoma. Full data from the study were presented at the 2026 ASCO Annual Meeting.

The Significance of the FDA Approval of Sonrotoclax for R/R MCL: Tycel Phillips, MD

Tycel Phillips, MD, an associate professor in the Department of Hematology and Hematopoietic Cell Transplantation in the Division of Lymphoma at City of Hope, discussed the May 2026 FDA approval of sonrotoclax (Beqalzi) for patients with mantle cell lymphoma (MCL) who have already received at least 2 prior lines of therapy. He highlighted the significance of the approval and in which cases the treatment can be best used.

Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers: Jennifer Eads, MD

Jennifer Eads, MD, a professor of clinical medicine (hematology-oncology), physician lead for Gastrointestinal (GI) Clinical Research, and director of the National Clinical Trials Network at Abramson Cancer Center of the University of Pennsylvania, discussed early data from a phase 1/2 trial (NCT06055439) evaluating the CDH17-directed CAR T-cell therapy CHM-2101 for the treatment of patients with relapsed/refractory GI cancers.

The Neoadjuvant Use of ICIs in Bladder Cancer: Matthew Galsky, MD

Matthew Galsky, MD, the director of Genitourinary Medical Oncology, co-director of the Center of Excellence for Bladder Cancer, the deputy director, and a professor of medicine (Hematology and Medical Oncology) at the Mount Sinai Tisch Cancer Center, discussed the emergence of immune checkpoint inhibitors (ICIs) the neoadjuvant setting of bladder cancer. The role of immune checkpoint blockade in muscle-invasive bladder cancer (MIBC) has continued to expand beyond the adjuvant setting and is now firmly established in perioperative treatment strategies, Galsky began. Recent clinical trials have demonstrated that integrating immunotherapy into treatment before and after surgery can significantly improve outcomes, leading to major shifts in the standard of care for patients with MIBC, he said.

The Role of Romiplostim in Managing CIT in GI Cancers: Gerald Soff, MD

Gerald Soff, MD, a professor of clinical medicine in the Division of Hematology and chief of the Classical Hematology Section at the University of Miami Miller School of Medicine, detailed the results of the phase 3 RECITE trial (NCT03362177). This pivotal study evaluated the efficacy of the thrombopoietin receptor agonist (TPO-RA) romiplostim in managing persistent chemotherapy-induced thrombocytopenia (CIT) among patients with gastrointestinal (GI) cancers. CIT represents a significant clinical hurdle, as low platelet counts often necessitate chemotherapy dose delays or reductions, potentially undermining the effectiveness of the oncologic treatment.